Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous lymphomas with poor overall prognosis, particularly in the setting of relapsed/refractory PTCL. Given the limited efficacy of current therapies, several different novel therapies encompassing multiple different mechanisms of action have been evaluated for relapsed and refractory PTCLs. In this review, we explore the current standard of care for relapsed/refractory PTCL, and evaluate in depth novel and emerging therapies, their scientific basis, and current trials for relapsed/refractory PTCL.
Keywords: T cell; adult T-cell lymphoma; angioimmunoblastic T-cell lymphoma; leukemia; lymphoma; novel therapy; peripheral T-cell lymphoma; peripheral T-cell lymphoma not otherwise specified; refractory; relapsed; therapeutics.